13F-HR filed by SR One Capital Management, LP
SR One Capital Management, LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-12, with 13 holding rows worth $706,376,583.
- Accession
- 0001193125-26-048808
- Filer
- CIK 1910264
- Filed
- 2026-02-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 13 entries on the cover page, a total value of $706,376,583 stated on the cover page (in dollars after the unit check, H1), rows summing to $706,376,583 with VALUE read as dollars as filed, 13F file number 028-21964. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 5,037,854 | $182,924,479 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 2,346,630 | $153,000,276 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 2,038,763 | $106,912,732 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 6,526,476 | $61,218,345 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 1,563,966 | $56,756,326 | dollars as filed | |
| ARS PHARMACEUTICALS INC | 82835W108 | COM | 4,012,903 | $46,750,320 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 4,514,929 | $37,753,841 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 1,959,896 | $19,128,585 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 430,330 | $13,043,302 | dollars as filed | |
| OCULIS HOLDING AG | H5870P102 | CMN | 641,022 | $12,801,209 | dollars as filed | |
| ENGENE HOLDINGS INC | 29286M105 | COM | 747,750 | $6,752,183 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,333,333 | $6,166,666 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 137,753 | $3,168,319 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001193125-26-048808 | this filing | 2026-02-12 | acceptance time not in the bulk data set |